Skip to main content

Table 3 Selected demographic and baseline characteristics of the patients grouped by reason for dose reduction

From: Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience

Categorical factor Dose reduction due to other reasons (N=28) CIPN dose reduction (N=21) p-value1
  N(row%) N(row%)  
Her2    
Negative 22 (58) 16 (42) 1.00
Positive 6 (55) 5 (45)  
Agent    
Paclitaxel only 4 (22) 14 (78) 0.001 2
Docetaxel only 20 (80) 5 (20)  
Multiple agents3 4 (67) 2 (33) 0.68
Alcohol    
No 27 (57) 20 (42) 1.00
Yes 1 (50) 1 (50)  
Diabetes    
No 22 (61) 14 (39) 0.51
Yes 6 (46) 7 (54)  
Race    
Black 14 (47) 16 (53) <0.001 4
White 14 (78) 4 (22)  
Other 0 1 (100)  
Continuous Factor Mean (range) Mean (range)  
Age (years) 55 (42–75) 55 (35-67) 0.84
  1. 1p-values calculated with the use of two-sided Fisher’s and Fisher-Freeman-Halton’s tests for categorical variables and the t-test for continuous variables.
  2. 2Patients treated with paclitaxel (or nab- paclitaxel) only vs. those treated with docetaxel only.
  3. 3Patients treated with multiple agents, compared to those treated with either paclitaxel only or docetaxel only.
  4. 4Black compared to white only.